[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200100687A1 - Комбинированная химиотерапия - Google Patents

Комбинированная химиотерапия

Info

Publication number
EA200100687A1
EA200100687A1 EA200100687A EA200100687A EA200100687A1 EA 200100687 A1 EA200100687 A1 EA 200100687A1 EA 200100687 A EA200100687 A EA 200100687A EA 200100687 A EA200100687 A EA 200100687A EA 200100687 A1 EA200100687 A1 EA 200100687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combined chemotherapy
mitosis
paclitaxel
formulas
inhibitors
Prior art date
Application number
EA200100687A
Other languages
English (en)
Inventor
Ричард Керельтон Гоувен
Джудит Зибольд-Лиопольд
Original Assignee
Варнер Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер Ламберт Компани filed Critical Варнер Ламберт Компани
Publication of EA200100687A1 publication Critical patent/EA200100687A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ингибиторы митоза, такие как паклитаксел, имеют улучшенную антиопухолевую активность при использовании в комбинации с избирательным МЕК ингибитором, в частности соединением фениламина формул I и II.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100687A 1998-12-22 1999-12-21 Комбинированная химиотерапия EA200100687A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
EA200100687A1 true EA200100687A1 (ru) 2001-12-24

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100687A EA200100687A1 (ru) 1998-12-22 1999-12-21 Комбинированная химиотерапия

Country Status (31)

Country Link
EP (1) EP1140291B1 (ru)
JP (1) JP2002532570A (ru)
KR (1) KR20010099877A (ru)
CN (1) CN1333698A (ru)
AP (1) AP2001002175A0 (ru)
AT (1) ATE310567T1 (ru)
AU (1) AU2203900A (ru)
BG (1) BG105715A (ru)
BR (1) BR9916839A (ru)
CA (1) CA2352326A1 (ru)
CZ (1) CZ20012139A3 (ru)
DE (1) DE69928568T2 (ru)
EA (1) EA200100687A1 (ru)
EE (1) EE200100339A (ru)
ES (1) ES2253928T3 (ru)
GE (1) GEP20043172B (ru)
HK (1) HK1042057A1 (ru)
HR (1) HRP20010473A2 (ru)
HU (1) HUP0104844A3 (ru)
ID (1) ID30250A (ru)
IL (1) IL143939A0 (ru)
IS (1) IS5969A (ru)
MA (1) MA26768A1 (ru)
NO (1) NO20013099L (ru)
NZ (1) NZ512859A (ru)
OA (1) OA11733A (ru)
PL (1) PL348326A1 (ru)
SK (1) SK8712001A3 (ru)
TR (1) TR200101871T2 (ru)
WO (1) WO2000037141A1 (ru)
YU (1) YU45401A (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
AU8856201A (en) 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JPWO2005035493A1 (ja) * 2003-10-08 2006-12-21 帝人ファーマ株式会社 アミノピロリジン誘導体の製造方法および中間体化合物
AU2004283148A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7956191B2 (en) * 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
JP5933459B2 (ja) 2010-02-25 2016-06-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｒａｆ阻害剤に対する耐性を付与するｂｒａｆ突然変異
KR20120139767A (ko) 2010-03-09 2012-12-27 더 브로드 인스티튜트, 인코퍼레이티드 1차 암 요법에 대한 저항성을 갖는 또는 발달시키는 환자에서 암을 진단 및 치료하는 방법
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2013328929B2 (en) 2012-10-12 2018-01-04 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU6580598A (en) * 1997-03-21 1998-10-20 Board Of Regents, The University Of Texas System (noey2) gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Also Published As

Publication number Publication date
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
DE69928568D1 (de) 2005-12-29
CZ20012139A3 (cs) 2002-01-16
ID30250A (id) 2001-11-15
IL143939A0 (en) 2002-04-21
NZ512859A (en) 2004-06-25
NO20013099L (no) 2001-08-20
AU2203900A (en) 2000-07-12
MA26768A1 (fr) 2004-12-20
OA11733A (en) 2005-05-12
CA2352326A1 (en) 2000-06-29
BG105715A (en) 2002-04-30
SK8712001A3 (en) 2002-02-05
DE69928568T2 (de) 2006-07-27
BR9916839A (pt) 2001-10-09
IS5969A (is) 2001-06-14
JP2002532570A (ja) 2002-10-02
EE200100339A (et) 2002-10-15
EP1140291A1 (en) 2001-10-10
YU45401A (sh) 2004-07-15
EP1140291B1 (en) 2005-11-23
ES2253928T3 (es) 2006-06-01
CN1333698A (zh) 2002-01-30
TR200101871T2 (tr) 2001-10-22
HK1042057A1 (zh) 2002-08-02
PL348326A1 (en) 2002-05-20
HUP0104844A3 (en) 2003-05-28
HRP20010473A2 (en) 2002-08-31
NO20013099D0 (no) 2001-06-21
AP2001002175A0 (en) 2001-06-21
WO2000037141A9 (en) 2000-12-07
KR20010099877A (ko) 2001-11-09
WO2000037141A1 (en) 2000-06-29
ATE310567T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
EA200100687A1 (ru) Комбинированная химиотерапия
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA199800667A1 (ru) Новые фенантридины
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
ATE164839T1 (de) Retrovirale proteaseinhibitoren
DE59904474D1 (de) Odorierung von gas
PE13399A1 (es) Inhibidores de pirazinona para trombina
EA199800633A1 (ru) Новые замещенные производные имидазола
EA200201252A1 (ru) Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4
NO983438D0 (no) Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
ATE234091T1 (de) Thrombin inhibitoren
ATE196628T1 (de) Hydroxyamidinderivate verwendbar als stickoxidsynthese inhibitoren
EA200101017A1 (ru) Ингибиторы связывания lfa-1 с icam и их использование
EA200000884A1 (ru) Производные стрептограминов, их получение и содержащие их композиции
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
ATE228760T1 (de) Thrombininhibitoren
BR9912307A (pt) Inibidores fkbp
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
ATE403422T1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
EA200500878A1 (ru) Кальцилитические соединения
EA200100073A1 (ru) Изохинолины в качестве ингибиторов урокиназы
CR6395A (es) Quimioterapia de combinacion